0001595097Three YearsQ1--12-31false0001595097us-gaap:AdditionalPaidInCapitalMember2022-12-310001595097crbp:OfficeFurnitureAndEquipmentMember2023-03-310001595097crbp:CFFWarrantMembercrbp:InvestmentAgreementMember2022-03-310001595097crbp:StockOptionsMember2022-01-012022-03-310001595097crbp:CspcLicenseAgreementMembersrt:MinimumMember2023-02-122023-02-120001595097srt:MaximumMembercrbp:LoanAgreementMembercrbp:KTwoWarrantMember2020-07-280001595097crbp:WarrantsMember2023-01-012023-03-310001595097srt:MaximumMembercrbp:JenrinAgreementMember2018-09-202018-09-200001595097crbp:TwoThousandFourteenEquityIncentivePlanMember2022-12-310001595097us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001595097us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097us-gaap:CommonStockMember2023-01-012023-03-310001595097crbp:LoanAgreementMember2021-11-012021-11-300001595097crbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2023-03-310001595097crbp:TwoThousandFourteenEquityIncentivePlanMembercrbp:JanuaryOneTwoThousandTwentyTwoMember2021-01-012021-12-310001595097us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097crbp:TwoThousandFourteenEquityIncentivePlanMembercrbp:JanuaryOneTwoThousandTwentyTwoMember2022-01-012022-12-310001595097us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001595097us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001595097us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097us-gaap:ShareBasedCompensationAwardTrancheTwoMembercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2020-07-280001595097us-gaap:LeaseholdImprovementsMember2023-03-310001595097us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097crbp:Debt1BMembercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-01-012022-12-310001595097us-gaap:RetainedEarningsMember2022-01-012022-03-310001595097us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097us-gaap:RetainedEarningsMember2023-01-012023-03-310001595097crbp:LoanAgreementMembercrbp:KTwoWarrantMember2020-07-2800015950972021-05-262021-05-260001595097us-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097crbp:DeferredTaxAssetsMember2023-01-012023-03-310001595097us-gaap:MeasurementInputRiskFreeInterestRateMembercrbp:CFFWarrantMember2023-03-310001595097us-gaap:MeasurementInputExpectedDividendRateMembercrbp:K2WarrantMember2023-03-310001595097crbp:OfficeFurnitureAndEquipmentMembersrt:MaximumMember2023-01-012023-03-310001595097crbp:CspcLicenseAgreementMember2023-03-310001595097us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001595097crbp:Debt1BMembersrt:MaximumMembercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-12-310001595097us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097us-gaap:LetterOfCreditMember2023-03-310001595097us-gaap:MeasurementInputExpectedTermMembercrbp:CFFWarrantMember2023-03-310001595097us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097us-gaap:MeasurementInputExpectedDividendRateMembercrbp:CFFWarrantMember2023-03-310001595097us-gaap:LeaseholdImprovementsMember2022-12-310001595097us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097us-gaap:WarrantMember2022-01-012022-03-310001595097crbp:LoanAgreementMember2022-11-012022-11-300001595097us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-3100015950972023-02-142023-02-140001595097crbp:ComputerHardwareAndSoftwareMember2023-03-310001595097country:GB2023-03-310001595097us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097crbp:TwoThousandFourteenEquityIncentivePlanMember2023-03-310001595097us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001595097us-gaap:ShareBasedCompensationAwardTrancheOneMember2020-07-2800015950972021-08-260001595097crbp:StockOptionsMember2023-01-012023-03-310001595097crbp:AmendedLoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2020-07-282020-07-2800015950972021-12-310001595097us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001595097crbp:CFFWarrantMember2018-01-2600015950972022-03-310001595097crbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-12-310001595097crbp:CFFWarrantMembercrbp:InvestmentAgreementMember2023-01-012023-03-310001595097us-gaap:StockOptionMember2023-03-310001595097crbp:CspcLicenseAgreementMembersrt:MaximumMember2023-02-122023-02-120001595097crbp:ComputerHardwareAndSoftwareMember2022-12-310001595097us-gaap:StockOptionMember2022-01-012022-03-310001595097us-gaap:LeaseholdsAndLeaseholdImprovementsMember2023-01-012023-03-310001595097us-gaap:StockOptionMember2023-01-012023-03-310001595097us-gaap:WarrantMember2023-01-012023-03-310001595097us-gaap:CorporateDebtSecuritiesMember2023-03-310001595097us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-3100015950972023-01-012023-03-310001595097us-gaap:RetainedEarningsMember2022-12-310001595097crbp:LendersMember2023-03-310001595097us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097crbp:TwoThousandFourteenEquityIncentivePlanMember2022-01-010001595097crbp:OfficeFurnitureAndEquipmentMembersrt:MinimumMember2023-01-012023-03-310001595097crbp:Debt1AMembercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-01-012022-12-310001595097us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097us-gaap:MeasurementInputRiskFreeInterestRateMembercrbp:K2WarrantMember2023-03-310001595097us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001595097crbp:K2WarrantMemberus-gaap:MeasurementInputPriceVolatilityMember2023-03-310001595097us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001595097crbp:LoanAgreementMemberus-gaap:ShareBasedCompensationAwardTrancheOneMembercrbp:KTwoHealthVenturesLLCMember2020-07-280001595097us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001595097crbp:CFFWarrantMembercrbp:InvestmentAgreementMember2023-03-310001595097crbp:CFFWarrantMember2023-01-012023-03-310001595097crbp:LoanAgreementMember2022-11-300001595097srt:MaximumMembercrbp:Debt1AMembercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-12-310001595097us-gaap:CommonStockMember2022-01-012022-03-310001595097crbp:InvestorRelationsServiceProviderMembercrbp:ProfessionalServicesAgreementMembercrbp:WarrantsMember2020-10-162020-10-160001595097us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001595097us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001595097crbp:InvestorRelationsServiceProviderMembercrbp:ProfessionalServicesAgreementMembercrbp:WarrantsMember2020-10-160001595097us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001595097us-gaap:CommonStockMember2022-12-310001595097crbp:TwoThousandFourteenEquityIncentivePlanMember2014-04-012014-04-300001595097us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097crbp:MilkyWayLicenseAgreementMember2021-05-252021-05-250001595097us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097us-gaap:AdditionalPaidInCapitalMember2021-12-310001595097crbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-01-012022-12-310001595097crbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2020-07-282020-07-280001595097crbp:WarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2023-03-310001595097srt:MaximumMembercrbp:JefferiesLLCMembercrbp:AugustTwoThousandAndTwentySaleAgreementMember2020-04-062020-04-070001595097us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097us-gaap:SeriesAPreferredStockMember2023-01-012023-03-310001595097us-gaap:AdditionalPaidInCapitalMember2023-03-310001595097us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097crbp:WarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-03-310001595097us-gaap:MeasurementInputExpectedTermMembercrbp:K2WarrantMember2023-03-310001595097crbp:DefaultLoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2023-01-012023-03-310001595097us-gaap:RetainedEarningsMember2021-12-310001595097crbp:CspcLicenseAgreementMember2023-01-012023-03-310001595097crbp:JenrinAgreementMember2018-09-202018-09-200001595097us-gaap:RetainedEarningsMember2022-03-310001595097crbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2020-07-280001595097us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001595097us-gaap:CorporateDebtSecuritiesMember2022-12-310001595097crbp:CspcLicenseAgreementMembersrt:MaximumMember2023-01-012023-03-310001595097us-gaap:CommonStockMember2023-03-310001595097us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001595097srt:MaximumMembercrbp:MilkyWayLicenseAgreementMember2021-05-252021-05-250001595097crbp:Debt1BMembersrt:MinimumMembercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-12-310001595097crbp:Debt1Membercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-01-012022-12-310001595097crbp:UCSFLincenseAgreementMember2021-05-262021-05-260001595097us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097crbp:CFFWarrantMemberus-gaap:MeasurementInputPriceVolatilityMember2023-03-310001595097us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001595097crbp:TwoThousandFourteenEquityIncentivePlanMember2023-01-010001595097crbp:CFFWarrantMembercrbp:InvestmentAgreementMember2022-01-012022-03-310001595097us-gaap:CommercialPaperMember2022-12-310001595097crbp:KTwoWarrantMember2023-01-012023-03-3100015950972022-12-3100015950972022-01-012022-03-310001595097crbp:InsurancePolicyMember2023-03-310001595097us-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097crbp:LoanAgreementMember2021-11-300001595097us-gaap:ShareBasedCompensationAwardTrancheThreeMembercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2020-07-280001595097crbp:OfficeFurnitureAndEquipmentMember2022-12-310001595097crbp:InsurancePolicyMember2022-12-310001595097crbp:Debt2Membercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-01-012022-12-310001595097crbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-01-012022-03-310001595097crbp:UCSFLincenseAgreementMembersrt:MaximumMember2021-05-262021-05-260001595097us-gaap:AdditionalPaidInCapitalMember2022-03-310001595097us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097crbp:LoanAgreementMembercrbp:KTwoWarrantMember2020-07-282020-07-2800015950972023-03-310001595097country:GB2022-12-310001595097us-gaap:RetainedEarningsMember2023-03-3100015950972023-05-050001595097crbp:ComputerHardwareAndSoftwareMember2023-01-012023-03-310001595097us-gaap:SeriesAPreferredStockMember2022-12-200001595097crbp:Debt2Membercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-12-310001595097us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001595097crbp:TwoThousandFourteenPlanMember2022-01-012022-03-310001595097srt:MinimumMembercrbp:Debt1AMembercrbp:LoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2022-12-310001595097us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097us-gaap:CommercialPaperMember2023-03-310001595097crbp:WarrantsMemberus-gaap:MeasurementInputExpectedTermMember2023-03-310001595097us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097us-gaap:SeriesAPreferredStockMember2022-10-120001595097us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097crbp:DefaultLoanAgreementMembercrbp:KTwoHealthVenturesLLCMember2023-03-310001595097us-gaap:CommonStockMember2021-12-310001595097us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-03-310001595097us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001595097us-gaap:MeasurementInputRiskFreeInterestRateMembercrbp:WarrantsMember2023-03-310001595097us-gaap:CommonStockMember2022-03-310001595097crbp:CspcLicenseAgreementMember2023-02-122023-02-12iso4217:USDxbrli:sharesxbrli:pureutr:sqftxbrli:sharesiso4217:USD
|
|
Item 2. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. |
The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly those under “Risk Factors.”
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as “may,” “can,” “anticipate,” “assume,” “should,” “indicate,” “would,” “believe,” “contemplate,” “expect,” “seek,” “estimate,” “continue,” “plan,” “point to,” “project,” “predict,” “could,” “intend,” “target,” “potential” and other similar words and expressions of the future.
There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:
|
|
● |
our history of operating losses; |
● |
our current and future capital requirements and our ability to satisfy our capital needs; |
● |
our ability to complete required clinical trials of our product and obtain approval from the FDA or other regulatory agents in different jurisdictions; |
● |
our ability to internally develop new product candidates, intellectual property, and other product candidates we may acquire and/or license; |
● |
our ability to maintain or protect the validity of our patents and other intellectual property; |
● |
our ability to retain key executive members; |
● |
interpretations of current laws and the passages of future laws; |
● |
acceptance of our business model by investors; |
● |
the accuracy of our estimates regarding expenses and capital requirements; and |
● |
our ability to adequately support growth. |
The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. Please see “Risk Factors” for additional risks which could adversely impact our business and financial performance.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs or projections will result or be achieved or accomplished.
Overview
Corbus Pharmaceuticals Holdings, Inc. (the “Company” or “Corbus”) is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways. Corbus’ internally developing pipeline includes CRB-701, a next generation antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. The Company has also developed CRB-913, an endocannabinoid small molecule drug, for the treatment of obesity and is seeking partners to fund further development.
-25-
Corbus' precision oncology internally developing pipeline:
•CRB-701 is a next generation ADC that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload. In February 2023, the Company obtained a license from CSPC Megalith Biopharmaceutical Co., Ltd ("CSPC"), a subsidiary of CSPC Pharmaceutical Group Limited, to develop and commercialize the drug in the United States ("U.S."), Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia (the “CSPC License Agreement”). The Investigational New Drug (IND) application for CRB-701 has been cleared by the U.S. FDA and the drug is currently being investigated by CSPC in a Phase 1 dose escalation clinical trial in patients with advanced solid tumors in China. Corbus is planning to bridge data from this Phase 1 trial to support a U.S. clinical trial starting in mid-2024.
•CRB-601 is an anti-αvβ8 monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells in the tumor microenvironment. In pre-clinical models, CRB-601 demonstrates enhanced anti-tumor activity when combined with anti-PD-1 checkpoint inhibitor therapy compared to either single agent alone. Pre-clinical data suggests that blockade of latent TGFβ production by CRB-601 can lead to changes in immune cell infiltration in the tumor microenvironment, potentially enhancing the benefit of PD-1 blockade. CRB-601 is being developed as a potential treatment for patients with solid tumors in combination with existing therapies, including checkpoint inhibitors, and is scheduled for an IND submission in the second half of 2023. The Company expects to enroll the first patient in the Phase 1 study by the end of 2023.
Corbus' endocannabinoid pipeline:
•CRB-913 is a second-generation cannabinoid receptor type 1 (CB1) inverse agonist designed to treat obesity and related metabolic diseases. In the diet-induced obesity mice model (DIO), CRB-913 demonstrates a reduction in weight and food consumption, improvement in insulin resistance and leptinemia, and reduced fat deposits in the liver. The CRB-913 program is in the pre-clinical stage, and we are seeking partnerships to fund further development.
Financial Operations Overview
We are a precision oncology company and have not generated any revenues from the sale of products. We have never been profitable and at March 31, 2023, we had an accumulated deficit of approximately $409,825,000. Our net losses for the three months ended March 31, 2023 and 2022, were approximately $17,745,000 and $9,437,000, respectively.
We expect to continue to incur significant expenses for the foreseeable future. We expect our total expenses in 2023 to stay consistent as compared to 2022, however, research and development expenses will increase as assets in our pipeline move into the clinical phase and other operating expenses to decrease as we expect legal and settlement costs from 2022 will not recur. We will continue to incur significant operating losses and accordingly we will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity or debt financings or other sources, which may include government grants and collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.
We expect to continue to incur operating losses for at least the next several years in connection with our ongoing activities, as we:
•conduct pre-clinical and clinical trials for our product candidates;
•continue our research and development efforts; and
•manufacture drugs for clinical studies.
Recent Developments
Continued Listing on The Nasdaq Capital Market
On January 3, 2022, we received a deficiency notice from the Listing Qualifications Staff (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), indicating that based upon the closing price of our common stock for the prior 30 consecutive business days, the Company was not in compliance with the minimum bid price requirements in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on The Nasdaq Global Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we were provided a grace period of 180 days, or until July 5, 2022, to regain compliance with the Minimum Bid Price Requirement. On July 8, 2022, we transferred the listing of our common stock to The Nasdaq Capital Market and were afforded the remainder of The Nasdaq Capital Market’s second 180 day calendar day compliance period, or until January 3, 2023, to demonstrate compliance with the Minimum Bid Price Requirement.
-26-
On January 4, 2023, we received a letter from the Staff indicating that, based upon the Company’s continued non-compliance with the Minimum Bid Price Requirement for continued listing on The Nasdaq Capital Market, the Staff had determined to delist the Company’s securities from Nasdaq unless we timely requested a hearing before the Nasdaq Hearings Panel (the “Panel”). We timely requested a hearing and appeared before the Panel on February 23, 2023. As discussed below under the heading “Reverse Stock Split,” we effected the Reverse Stock Split on February 14, 2023. On March 7, 2023, we received a notice from the Panel that we had regained compliance with the Minimum Bid Price and met all other applicable continued listing requirements for The Nasdaq Capital Market and that the matter was closed.
CSPC License Agreement
On February 12, 2023, we entered into the CSPC License Agreement with CSPC pursuant to which we received an exclusive license to obtain certain exclusive rights to develop and commercialize CRB-701 (SYS6002), a novel clinical stage antibody drug conjugate targeting Nectin-4. The CSPC License Agreement covers exclusive commercialization rights to CRB-701 in the United States, Canada, the European Union (including the European Free Trade Area), the United Kingdom, and Australia.
We will pay CSPC an upfront payment of $7,500,000 ($5,000,000 at signing during the first quarter 2023 followed by a $2,500,000 payment after eighteen months). CSPC will also be eligible to receive low, double-digit royalties on net sales and up to $130,000,000 in potential development and regulatory milestone payments and $555,000,000 in potential commercial milestone payments.
Reverse Stock Split
On February 9, 2023, our Board of Directors approved a 1-for-30 reverse stock split, and we filed the Amendment for the Reverse Stock Split with the Secretary of State of the State of Delaware. The Reverse Stock Split became effective in accordance with the terms of the Amendment on February 14, 2023. The Amendment did not change the number of authorized shares of common stock or the par value. All references in the condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the Reverse Stock Split.
Results of Operations
Comparison of Three Months Ended March 31, 2023 and 2022
Revenue from Awards. To date, we have not generated any revenues from the sales of products. We do not expect to generate revenue from product sales unless and until we successfully complete development and obtain regulatory approval for the marketing of our product candidates, which we expect will take a number of years and is subject to significant uncertainty.
Research and Development. Research and development expenses for the three months ended March 31, 2023 totaled approximately $13,388,000, an increase of $10,102,000 over the $3,286,000 recorded for the three months ended March 31, 2022. The increase in fiscal 2023 as compared to fiscal 2022 was primarily attributable to increases in licensing costs of $7,500,000 associated with the CSPC License Agreement, $1,200,000 associated with the achievement of a development milestone under the USCF License Agreement, and $763,000 in manufacturing costs as CRB-601 advances toward the clinical stage.
During 2018, the Company formed a subsidiary in each of the United Kingdom and Australia and approximately 16% and 33% of research and development expenses recorded for the three months ended March 31, 2023 and 2022, respectively was recorded in these entities.
General and Administrative. General and Administrative expense for the three months ended March 31, 2023 totaled approximately $3,909,000, a decrease of $1,322,000 over the $5,231,000 recorded for the three months ended March 31, 2022. The decrease in fiscal 2023 as compared to fiscal 2022 was primarily attributable to decreases in legal costs of $607,000 related to the litigation with Venn Therapeutics, LLC, stock-based compensation costs of $483,000 as stock options are being granted at lower current fair values as compared to earlier grants that are now fully vested, and $215,000 in reduced premiums associated with insurance policies.
Other Expense, Net. Other expense, net for the three months ended March 31, 2023 was approximately $448,000 as compared to approximately $920,000 recorded for the three months ended March 31, 2022. The decrease of $472,000 in 2023 as compared to 2022 was primarily attributable to investment income in 2023 as compared to investment losses in 2022.
-27-
Liquidity and Capital Resources
Since inception, we have experienced negative cash flows from operations. We have financed our operations primarily through sales of equity-related securities. At March 31, 2023, our accumulated deficit since inception was approximately $409,825,000.
At March 31, 2023, we had total current assets of approximately $45,865,000 and current liabilities of approximately $14,359,000, resulting in working capital of approximately $31,506,000. Of our total cash, cash equivalents, investments, and restricted cash of $44,897,000 at March 31, 2023, approximately $42,911,000 was held within the United States.
Net cash used in operating activities for the three months ended March 31, 2023 was approximately $15,115,000, which includes a net loss of approximately $17,745,000, adjusted for non-cash expenses of approximately $1,206,000 largely related to stock-based compensation expense, and approximately $1,424,000 of cash provided by net working capital items principally due to an increase in other long-term liabilities.
Cash provided by investing activities for the three months ended March 31, 2023 totaled approximately $5,550,000, which was principally related to proceeds from the sales and maturities of marketable securities.
Cash used in financing activities for the three months ended March 31, 2023 totaled approximately $113,000, which was related to the repayment of short-term borrowings.
We expect our cash, cash equivalents, and marketable securities of approximately $44,227,000 at March 31, 2023 will be sufficient to meet our operating and capital requirements through the second quarter of 2024, based on current planned expenditures.
We will need to raise significant additional capital to continue to fund operations and the discovery and pre-clinical costs for our product candidates. If we are unable to raise sufficient capital in the future, we may be required to undertake cost-cutting measures, including delaying or discontinuing certain clinical activities. We may seek to sell common stock, preferred stock or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. In addition, we may seek to raise cash through collaborative agreements or from government grants. The sale of equity and convertible debt securities may result in dilution to our stockholders and certain of those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights.
The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of our clinical development programs.
Funding may not be available when needed, at all, or on terms acceptable to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate expenses including some or all of our planned clinical trials.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors, other than future royalty payments under license agreements discussed as follows:
License Agreement with Jenrin
Pursuant to the terms of the Jenrin Agreement, we are obligated to pay potential milestone payments to Jenrin totaling up to $18.4 million for each compound we elect to develop based upon the achievement of specified development and regulatory milestones. In addition, we are obligated to pay Jenrin royalties in the mid, single digits based on net sales of any Licensed Products, as defined in the Jenrin Agreement, subject to specified reductions.
The Jenrin Agreement terminates on a country-by-country basis and product-by-product basis upon the expiration of the royalty term for such product in such country. Each royalty term begins on the date of the first commercial sale of the licensed product in the applicable country and ends on the later of seven years from such first commercial sale or the expiration of the last to expire of the applicable patents in that country. The Jenrin Agreement may be terminated earlier in specified situations, including termination for uncured material breach of the Jenrin Agreement by either party, termination by Jenrin in specified circumstances, termination by Corbus with advance notice and termination upon a party’s insolvency or bankruptcy.
-28-
License Agreement with Milky Way
Pursuant to the terms of the Milky Way Agreement, we are obligated to pay potential milestone payments to Milky Way totaling up to $53.0 million based upon the achievement of specified development and regulatory milestones. In addition, we are obligated to pay Milky Way royalties in the lower, single digits based on net sales of any Licensed Products, as defined in the Milky Way Agreement.
The Milky Way Agreement will remain in effect on a Licensed Product-by-License Product and country-by-country basis, until the expiration of the Royalty Term of the Licensed Product in the country. The "Royalty Term" means the period beginning from the First Commercial Sale of the Licensed Product in the country until the expiration of the last-to-expire Valid Claim in any Licensor Patent in the country that Covers the composition of matter of the Licensed product, the manufacture of the Licensed Product in the country, or a method of use of the Licensed Product for an indication for which Regulatory Approval has been obtained in the country. The Milky Way Agreement may be terminated earlier in specified situations, including termination for material breach or termination by Corbus with advance notice.
License Agreement with UCSF
Pursuant to the terms of the UCSF Agreement, we are obligated to pay potential milestone payments to UCSF totaling up to $153.15 million based upon the achievement of specified development and regulatory milestones, excluding indication milestones for antibodies used for diagnostic products and services that will be an additional $50,000 for each new indication. In addition, we are obligated to pay UCSF royalties in the lower, single digits based on net sales of any Licensed Products, as defined in the UCSF License Agreement, and any diagnostic products and services.
The UCSF Agreement will remain in effect until the expiration or abandonment of the last of the Patent Rights licensed. The Royalty Term is the duration of Patent Rights in that country covering the applicable Licensed Product or Licensed Services Sold in the country. The UCSF Agreement may be terminated earlier in specified situations, including termination for material breach, termination by Corbus with advance notice and termination upon a party's bankruptcy.
License Agreement with CSPC
Pursuant to the terms of the CSPC License Agreement, we are obligated to pay potential milestone payments to CSPC totaling up to $130 million based upon the achievement of specified development and regulatory milestones and $555 million in potential commercial milestone payments. In addition, we are obligated to pay CSPC royalties in the low, double digits based on net sales of any Licensed Products, as defined in the CSPC License Agreement.
The CSPC License Agreement will remain in effect on a Licensed Product and on a country-by-country basis, until the expiration of the Royalty Term of the Licensed Product in the country. The Royalty Term is the period beginning from the First Commercial Sale of the Licensed Product in the country until the later of the expiration of the last-to-expire Valid Claim in any Licensor Patent in the country that Covers the Licensed product, 10 years after the date of the First Commercial Sale in the country, or expiration of the Regulatory Exclusivity for the Licensed Product in the country. The CSPC License Agreement may be terminated earlier in specified situations, including termination for material breach, termination by Corbus with advance notice and termination upon a party's bankruptcy.
Critical Accounting Policies and Estimates
Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, revenue, costs of expenses and related disclosures in the condensed consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates and judgments on historical experience, current economic and industry conditions and on various other factors that are believed to be reasonable under the circumstances. This forms the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe our critical accounting policies that involve the most judgment and complexity are those relating to:
|
|
● |
stock-based compensation; |
● |
accrued research and development expenses; and |
● |
right of use assets and lease liabilities |
-29-
Stock-Based Compensation
Stock options are granted with an exercise price at no less than fair market value at the date of the grant. The stock options normally expire ten years from the date of grant. Stock option awards vest upon terms determined by our Board.
We recognize compensation costs resulting from the issuance of stock-based awards to employees, members of our Board and consultants. The fair value of each option grant was estimated as of the date of grant using the Black-Scholes option-pricing model. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. We estimate volatility by analyzing the volatility of the trading price of our common stock. We use historical data, as well as subsequent events occurring prior to the issuance of the condensed consolidated financial statements, to estimate option exercise and employee forfeitures within the valuation model. The expected term of options granted to employees under our stock plans is based on the average of the contractual term (generally 10 years) and the vesting period (generally 48 months). The expected term of options granted under the 2014 Plan, all of which qualify as “plain vanilla” per SEC Staff Accounting Bulletin 107, is based on the average of the 6.25 years. For non-employee options, the expected term is the contractual term. The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option. We estimate the forfeiture rate at the time of grant and revise it, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures were estimated based on management’s expectation through industry knowledge and historical data. We have never paid dividends on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.
Accrued Research and Development Expenses
As part of the process of preparing financial statements, we are required to estimate and accrue expenses, the largest of which are research and development expenses. This process involves: communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual cost; estimating and accruing expenses in our financial statements as of each balance sheet date based on facts and circumstances known to us at the time; and periodically confirming the accuracy of our estimates with selected service providers and making adjustments, if necessary.
Examples of estimated research and development expenses that we accrue include:
•fees paid to CROs and research institutions in connection with pre-clinical studies;
•fees paid to contract manufacturers in connection with the production of drugs for studies and clinical trials;
•fees paid to CRO and research institutions in connection with conducting of clinical studies; and
•professional service fees for consulting and related services.
We base our expense accruals related to pre-clinical and clinical studies on our estimates of the services performed pursuant to contracts with multiple research institutions and clinical research organizations that conduct and manage pre-clinical and clinical studies on our behalf. The financial terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these contracts depend on factors, such as the successful enrollment of patients and the completion of clinical study milestones. Our service providers invoice us monthly in arrears for services performed. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If we do not identify costs that we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services, our actual expenses could differ from our estimates.
To date, we have not experienced significant changes in our estimates of accrued research and development expenses following each applicable reporting period. However, due to the nature of estimates, we cannot assure you that we will not make changes to our estimates in the future as we become aware of additional information regarding the status or conduct of our clinical studies and other research activities.
-30-
Leases
We lease our office space. We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, other current liabilities and operating lease liabilities in our condensed consolidated balance sheets.
ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As our leases do not provide an implicit rate, we use an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. This is the rate we would have to pay if borrowing on a collateralized basis over a similar term to each lease. The ROU asset also includes any lease payments made and excludes lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term.
The Company has subleased a portion of its leased facility under an agreement considered to be an operating lease according to U.S. GAAP. The Company has not been legally released from its primary obligations under the original lease and therefore it continues to account for the original lease as it did before commencement of the sublease. The Company will record both fixed and variable payments received from the sublessee in its statement of operations on a straight-line basis as an offset to rent expense.